Summary
Thermo Fisher Scientific Inc. (TMO) reported solid financial results for the first quarter of 2019, showcasing robust revenue growth and improved operating income. Total revenues reached $6.13 billion, a 5% increase year-over-year, driven by strong organic demand across all end markets, particularly in Asia. The company also benefited from strategic acquisitions, though partially offset by unfavorable currency translation effects. Profitability improved significantly, with operating income rising by 17% to $920 million and operating margin expanding to 15.0% from 13.4% in the prior year. This was attributed to higher sales, productivity gains, and lower restructuring costs, partially offset by strategic growth investments. The company also announced significant strategic moves, including the acquisition of Brammer Bio and an agreement to acquire Gatan, Inc., underscoring its commitment to inorganic growth and expanding its capabilities in key areas like gene and cell therapies and electron microscopy.
Financial Highlights
55 data points| Revenue | $6.13B |
| Gross Profit | $2.71B |
| R&D Expenses | $248.00M |
| SG&A Expenses | $1.53B |
| Operating Expenses | $5.21B |
| Operating Income | $920.00M |
| Interest Expense | $189.00M |
| Net Income | $815.00M |
| EPS (Basic) | $2.04 |
| EPS (Diluted) | $2.02 |
| Shares Outstanding (Basic) | 400.00M |
| Shares Outstanding (Diluted) | 403.00M |
Key Highlights
- 1Total revenues increased by 5% to $6.13 billion in Q1 2019, with organic revenue growth of 7% accounting for the majority of the increase, demonstrating strong underlying business momentum.
- 2Operating income grew by 17% to $920 million, and operating margin expanded by 160 basis points to 15.0%, reflecting improved profitability and operational efficiency.
- 3The company made significant strategic acquisitions, notably Brammer Bio for $1.7 billion and agreements to acquire Gatan, Inc., reinforcing its market leadership and expanding its offerings in high-growth areas.
- 4Net income increased by 41% to $815 million, leading to a substantial rise in diluted earnings per share (EPS) to $2.02 from $1.43 in the prior year's quarter.
- 5Cash flow from operations significantly improved, increasing to $649 million from $78 million in Q1 2018, indicating strong cash generation capabilities.
- 6The company maintained a strong balance sheet with total assets of $55.6 billion and total shareholders' equity of $27.7 billion as of March 30, 2019.
- 7Strategic investments in growth initiatives and productivity improvements are highlighted as key drivers for future performance, alongside a disciplined approach to capital allocation, including share repurchases and dividend payments.